Spondyloarthritis & psoriatic arthritis
Upadacitinib in psoriatic arthritis with prior TNF-inhibitor failure: a 56-week real-world study
Authors' conclusion
Upadacitinib demonstrated sustained efficacy across musculoskeletal and skin domains in PsA patients with prior inadequate response to TNF inhibitors, with a safety profile consistent with previous reports.
Study context
- Population
- Patients with psoriatic arthritis (PsA) and prior TNFi failure (mean age 46.7 ± 10.1 years, 59.6% female, mean disease duration 9.8 ± 7.4 years)
- Participants
- 47 patients
- Outcome
- ITT ACR20/50/70 response rates
- Follow-up
- Week 12
Methodological detailssingle-arm, real-world, intention-to-treat analysis
- Single-arm
- Real-world
- Intention-to-treat analysis
Main finding
As reported in the abstract
ACR20
63.8%
ACR50
55.3%
ACR70
31.9%
Observational data: associations, not effects.
Further findings
ITT ACR20/50/70 response rates · week 56
- ACR20
- 61.7%
- ACR50
- 59.6%
- ACR70
- 51.1%
- Intention-to-treat
DAPSA, BASDAI, ASDAS-CRP and PASI scores
- Significant improvements in DAPSA, BASDAI, ASDAS-CRP and PASI (all p<0.001)
- Resolution of enthesitis in most patients
Safety
- Adverse events
- 23.4%
- Leading to discontinuation
- 10.6%
- No new safety signals identified
Original publication
Upadacitinib in psoriatic arthritis with prior TNF-inhibitor failure: a 56-week real-world study. Clin Exp Rheumatol. Published 7 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →